Patent 7550261 was granted and assigned to Smithkline Beecham Limited on June, 2009 by the United States Patent and Trademark Office.
Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes.